Skip to main content

Table 4 PK parameters of AD16 (20 mg) in FE arm

From: Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study

PK parameters

Fasted

(N = 16)

Fed

(N = 16)

Tmax (h)

0.87 (0.50–2.00)

2.00 (0.50–4.00)

T1/2z (h)

7.41 ± 2.02 (27.23)

7.19 ± 2.02 (28.04)

Cmax (ng/mL)

560.60 ± 124.96 (22.29)

403.10 ± 89.63 (22.23)

AUC0-t (h*ng/mL)

4143.77 ± 931.63 (22.48)

4154.41 ± 1286.46 (30.97)

AUC0-∞ (h*ng/mL)

4224.51 ± 981.28 (23.23)

4263.01 ± 1338.75 (31.40)

AUC_%Extrap (%)

1.81 ± 1.57 (84.94)

2.56 ± 1.70 (66.69)

CL/F (mL/h)

4976.05 ± 1139.73 (22.90)

5153.49 ± 1683.51 (32.67)

Vd/F (mL)

50,548.34 ± 6031.25 (11.93)

49,778.22 ± 7718.92 (15.51)

λz (1/h)

0.10 ± 0.03 (25.31)

0.10 ± 0.03 (25.66)

MRT0-t (h)

8.64 ± 1.94 (22.44)

9.65 ± 2.41 (24.99)

MRT0-∞ (h)

9.41 ± 2.40 (25.52)

10.61 ± 2.70 (25.44)

  1. Data are expressed as mean ± SD (CV%) unless otherwise specified. Tmax (h) is expressed as median (range)